Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Precision BioSciences: Q1 Earnings Snapshot AP - Tue May 5, 6:09AM CDT

Precision BioSciences: Q1 Earnings Snapshot

DTIL : 8.20 (+4.33%)
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update Business Wire - Tue May 5, 6:01AM CDT

- Continued advancement of the Phase 1/2a ELIMINATE-B trial of PBGENE-HBV across multiple dosing cohorts; Late-Breaking poster presentation for PBGENE-HBV accepted at European Association...

TGTX : 42.54 (-1.39%)
DTIL : 8.20 (+4.33%)
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 Business Wire - Thu Apr 30, 6:01AM CDT

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet...

DTIL : 8.20 (+4.33%)
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study Business Wire - Wed Apr 29, 6:01AM CDT

- Arkansas Children’s Hospital activated as the first clinical trial site and now enrolling patients in the FUNCTION-DMD study of PBGENE-DMD -

DTIL : 8.20 (+4.33%)
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting Business Wire - Tue Apr 28, 6:01AM CDT

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet...

DTIL : 8.20 (+4.33%)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Apr 24, 6:01AM CDT

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies...

DTIL : 8.20 (+4.33%)
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 Business Wire - Wed Apr 22, 6:01AM CDT

- Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B -...

DTIL : 8.20 (+4.33%)
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries Business Wire - Wed Apr 15, 6:01AM CDT

- France and Romania planned for inclusion in the global ELIMINATE-B trial supporting broader patient enrollment -

DTIL : 8.20 (+4.33%)
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference Business Wire - Wed Apr 8, 6:01AM CDT

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet...

DTIL : 8.20 (+4.33%)
Precision BioSciences: Q4 Earnings Snapshot AP - Thu Mar 12, 6:27AM CDT

Precision BioSciences: Q4 Earnings Snapshot

DTIL : 8.20 (+4.33%)

Barchart Exclusives

Inflation Has Pushed this Dividend Aristocrat to 52-Week Lows. Why It’s Still Not Quite Time to Buy. Barchart - Tue May 12, 6:30PM CDT
McDonald's stock is trading near its 52-week lows and has a dividend yield of aroudn 2.7%. However, the stock does not look like a compelling buy yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.